A combination vaccine developed by Biontech/Pfizer, which could in future be used to vaccinate against Covid-19 and flu at the same time, has been included in an accelerated approval process by the US Food and Drug Administration.

This was announced by the Mainz-based German company Biontech and its US partner Pfizer (New York).

The vaccine combines an mRNA-based influenza vaccine with a corona vaccine adapted to both the currently predominant omicron sublines BA.4/BA.5 and to the wild type.

At the beginning of November, the two companies announced the start of a phase 1 study of the vaccine. Around 180 people between the ages of 18 and 64 should take part in the USA.